INVESTOR CONTACT:Jonathon Singer, Sagent847firstname.lastname@example.org
SCHAUMBURG, Ill., July 18, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) today announced the launch of Amikacin Sulfate Injection, USP, an anti-infective/antibiotic, in 500 mg per 2 mL and 1 g per 4 mL preservative-free vials. According to IMS, for the 12 months ending May 2016, the US market for Amikacin approximated $8 million. As with all products in Sagent's portfolio, Amikacin features Sagent's PreventIV Measures SM Packaging and Labeling, designed to help reduce the risk of medication errors. About Amikacin Sulfate Injection, USPAmikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species and Acinetobacter ( Mima-Herellea) species. The package insert, available at www.SagentPharma.com, contains the indications, boxed warnings, complete side effect profile and prescribing information. About Sagent Pharmaceuticals, Inc. Sagent Pharmaceuticals, Inc., founded in 2006, is a leading provider of affordable pharmaceuticals to the hospital market. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.